Daniel R. Chevallard
2017
In 2017, Daniel R. Chevallard earned a total compensation of $580.6K as Chief Financial Officer at Regulus Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $96,000 |
|---|---|
| Option Awards | $197,474 |
| Salary | $281,897 |
| Other | $5,262 |
| Total | $580,633 |
Chevallard received $281.9K in salary, accounting for 49% of the total pay in 2017.
Chevallard also received $96K in non-equity incentive plan, $197.5K in option awards and $5.3K in other compensation.
Rankings
In 2017, Daniel R. Chevallard's compensation ranked 11,320th out of 14,666 executives tracked by ExecPay. In other words, Chevallard earned more than 22.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,320 out of 14,666 | 23rd |
Division Manufacturing | 4,440 out of 5,772 | 23rd |
Major group Chemicals And Allied Products | 1,615 out of 2,075 | 22nd |
Industry group Drugs | 1,332 out of 1,731 | 23rd |
Industry Pharmaceutical Preparations | 1,043 out of 1,333 | 22nd |
Source: SEC filing on April 20, 2018.
Chevallard's colleagues
We found four more compensation records of executives who worked with Daniel R. Chevallard at Regulus Therapeutics in 2017.